Thus, we propose that CXCR4 may represent a therapeutic target for lung cancer patients, and that RNAi with siRNA targeting CXCR4 may establish an effective strategy for the treatment of lung cancer. This evidence concerns the gene CXCR4 and lung carcinoma.